SalaryGuide
SalariesCompaniesJobs
AboutPricingBlogFor Employers

Marketing jobs

3 marketing jobs

Tempus AI logo
4 weeks ago

Senior Director, Marketing - Germline Portfolio

Tempus AI

Chicago, IL (Hybrid)Full time$190K/yr – $260K/yr
Tempus AI logo
6 weeks ago

Product Marketing Manager, Life Sciences

Tempus AI

Chicago, IL (On-site)Full time$90K/yr – $150K/yr
Tempus AI logo
3 months ago

Product Marketing Manager, Life Sciences Research

Tempus AI

Chicago, IL (On-site)Full time$100K/yr – $150K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

3 jobs
Tempus AI logo

Senior Director, Marketing - Germline Portfolio

Tempus AI

Chicago, IL (Hybrid)

$190K/yr - $260K/yrIn-houseFull-timeSenior level10+ years exp.
4 weeks ago
Tempus AI logo

Product Marketing Manager, Life Sciences

Tempus AI

Chicago, IL (On-site)

$90K/yr - $150K/yrIn-houseFull-timeMid level5+ years exp.
6 weeks ago
Tempus AI logo

Product Marketing Manager, Life Sciences Research

Tempus AI

Chicago, IL (On-site)

$100K/yr - $150K/yrIn-houseFull-timeMid level5+ years exp.
3 months ago
Tempus AI logo
Tempus AI

Senior Director, Marketing - Germline Portfolio

Chicago, IL (Hybrid)

$190K/yr – $260K/yrSenior Level10+ years expFull time

Posted 4 weeks ago

  • Job
  • Company
  • Salaries
  • People
  • Funding
  • Audience
  • News
  • Links

Job Summary

Own the germline portfolio commercial narrative and GTM for hereditary cancer and rare-disease testing at the point of care, connecting R&D, Medical Affairs, and Operations while equipping the field with impact-focused materials and training.

  • Lead messaging, physician marketing, patient advocacy engagement, and digital clinician tools.
  • Ensure scientific accuracy and regulatory alignment across FDA, CLIA, CAP in cross-functional collaboration.

Job Description

Responsibilities

  • Differentiated Positioning & Narrative Execution: Develop and execute a comprehensive commercial roadmap for the germline portfolio, with a particular emphasis on hereditary cancer and rare disease testing at the point-of-care (in-clinic use cases). Own the overarching narrative to ensure the market understands our unique value proposition in VUS resolution and family-member testing programs.
  • Downstream Commercial Strategy: Drive product positioning, messaging, and go-to-market (GTM) strategies. Lead the development of physician marketing, patient-advocacy engagement, and digital clinician portals to streamline genetic counseling workflows.
  • Sales Enablement & Training: Partner deeply with Sales and Learning & Development (L&D) to equip the field organization with high-impact materials and aligned messaging to maximize clinical adoption.
  • Cross-Functional Synergy: Act as a bridge between R&D, Medical Affairs, and Laboratory Operations to ensure marketing strategies remain scientifically accurate and comply with regulatory requirements (FDA, CLIA, CAP).
  • Followership Over Mandate: You possess the organic authority and humility to listen deeply, collaborate cross-functionally, and rally multiple departments behind a unified marketing vision.
  • Low Ego, High Impact: You view marketing as a team sport, working seamlessly with technical, medical, and sales peers to turn growth strategy into commercial success without needing to own the entire upstream architecture .

Requirements

  • Education: Bachelor’s degree in Life Sciences required; MBA, MS in Genetic Counseling, or PhD preferred to bridge the gap between complex science and business strategy.
  • Experience: 10+ years of direct marketing experience in healthcare or life sciences, with at least 5 years in a senior leadership role focused on oncology, advanced diagnostics, or germline genetics.
  • Domain Expertise: Deep understanding of Next-Generation Sequencing (NGS) workflows, cancer genomics, and the evolving landscape of hereditary cancer testing.
  • AI-First Mindset: Practical familiarity with utilizing or operationalizing digital tools and modern AI-driven workflows to enhance the customer experience and marketing efficiency.

Preferred

  • MBA, MS in Genetic Counseling, or PhD preferred to bridge the gap between complex science and business strategy.
Tempus AI logo

Tempus AI

3.1 Glassdoor

Tempus is making precision medicine a reality by applying AI in healthcare, deriving insights from our expansive library of clinical data and molecular data. We enable physicians to make real-time, data-driven decisions to deliver personalized care and targeted therapies for patients through our analytical machine learning platform that uses the power of artificial intelligence in healthcare. We also work with partners to facilitate discovery, development, and delivery of optimized therapeutic options for patients through distinctive solution sets. Our mission is for each patient to benefit from the treatment of others who came before by providing the healthcare industry tools that learn as we gather more data. It’s About Time. For more information, visit tempus.com and follow us on Twitter (@TempusLabs).

Founded in 2015
Chicago, Illinois, USA
2.9K employees (97 in marketing)
www.tempus.com
52% recommend to a friend
51% CEO approval

Salaries

Posted range

$190K/yr – $260K/yr

Taken straight from the job posting.

See all Tempus AI salaries

Marketing Team

Marketing Team Size
32 (1% of company)
Median Tenure
3.6 years
Marketing Roles Posted (Last 30 Days)
2

Funding

Total Funding
$2.3B
Last Raise
$650M
Post IPO Debt, 9 months ago

Funding History

  • Jun 2025
    Post IPO Debt • $650M
  • Feb 2025
    Post IPO Debt • $300M
  • Oct 2022
    Debt Financing • $175M

Traffic Signals

Monthly Visitors
148.6K
Monthly Google Ads Budget
$4.7K
Traffic Source Mix
Search
50.6%
Direct
38.6%
Referral
7.9%
Social
1.9%
Paid
1%

Headcount Trend

Current headcount: ~2.9K

Recent News

Tempus AI: Great Buying Opportunity On Recent Weakness (NASDAQ:TEM)
Nov 13, 2025 • Seeking Alpha
Tempus AI: A Good Bet For The Future Of Health Care (NASDAQ:TEM)
Nov 12, 2025 • Seeking Alpha
Tempus AI: First Positive EBITDA, Huge TAM - Yet The Stock Isn’t A Buy (NASDAQ:TEM)
Nov 10, 2025 • Seeking Alpha
Tempus AI (TEM): Mounting Losses Challenge Bullish Growth Narrative Despite Strong Earnings Forecasts
Nov 6, 2025 • simplywall.st
Tempus AI: Volatility Equates to Opportunity in AI Leader
Nov 6, 2025 • Yahoo Finance
Canaccord Genuity lowers Tempus AI stock price target to $95 on growth outlook
Nov 5, 2025 • Investing.com
Is Tempus AI’s Share Price Justified After 146% Surge and New Healthcare Partnerships?
Nov 5, 2025 • simplywall.st
Tempus AI (TEM): Losses Deepen, Profitability Still Elusive Despite 62.68% Earnings Growth Forecast
Nov 5, 2025 • Yahoo Finance
Does Tempus AI’s Recent Healthcare Partnerships Signal More Upside For Its Share Price in 2025?
Nov 4, 2025 • Yahoo Finance
Earnings call transcript: Tempus AI Q3 2025 earnings beat forecasts, stock dips
Nov 4, 2025 • Investing.com
Tempus Reports Third Quarter 2025 Results
Nov 4, 2025 • Business Wire
Tempus AI Inc (TEM) Q3 2025 Earnings Report Preview: What To Expect
Nov 3, 2025 • Yahoo Finance
Tempus AI (TEM) Price Target Increased by 13.21% to 87.18
Oct 29, 2025 • Nasdaq
Tempus AI Enhances AI-Driven Diagnostics With Multiple FDA Approvals
Oct 27, 2025 • Yahoo Finance
Tempus AI Enhances AI-Driven Diagnostics With Multiple FDA Approvals
Oct 27, 2025 • Zacks Investment Research
Tempus AI, Inc. Stock (TEM) Opinions on FDA Clearance Milestone
Oct 23, 2025 • Quiver Quantitative
Tempus AI Stock Before Q3 Earnings Release: To Buy or Not to Buy?
Oct 20, 2025 • Zacks Investment Research
Why Tempus AI Stock Raced More Than 5% Higher Today
Oct 20, 2025 • The Motley Fool
Tempus AI Hits $100—Are Shares Due for a Pullback?
Oct 15, 2025 • MarketBeat
After Leaping 29% Tempus AI, Inc. (NASDAQ:TEM) Shares Are Not Flying Under The Radar
Oct 9, 2025 • simplywall.st
Tempus AI (NASDAQ:TEM) Receives Sell (D-) Rating from Weiss Ratings
Oct 9, 2025 • MarketBeat
Tempus AI stock hits all-time high at 98.14 USD
Oct 8, 2025 • Investing.com
Tempus AI stock has now risen over 200% since purchase by Pelosi
Oct 8, 2025 • Quiver Quantitative
Growth or Bubble? Decoding Tempus AI’s Surge
Oct 8, 2025 • StocksToTrade
Tempus AI shares surge to all-time high
Oct 8, 2025 • Sherwood News
Tempus AI, Inc. Stock (TEM) Opinions on FDA Clearance and Insider Sales
Oct 6, 2025 • Quiver Quantitative
Tempus AI, Inc. (TEM) Secures FDA Clearance for xR IVD Device to Enhance Drug Discovery
Oct 4, 2025 • Yahoo Finance
Why Tempus AI Stock Was Motoring Higher This Week
Oct 3, 2025 • The Motley Fool
Tempus AI Stock (TEM) Spikes 9%— Should You Buy Now?
Oct 2, 2025 • TipRanks
Tempus AI CEO Lefkofsky sells shares worth $25.4 million
Sep 29, 2025 • Investing.com
Tempus AI (TEM): Assessing Valuation as Investor Interest Grows Without Clear Catalysts
Sep 29, 2025 • Yahoo Finance
Affirm Holdings, Oklo, Tempus AI Are Among Top 10 Large Cap Losers Last Week (Sep. 22- Sep. 26): Are The Others In Your Portfolio?
Sep 28, 2025 • Benzinga.com
What Are 2 Great Tech Stocks to Buy Right Now?
Sep 27, 2025 • The Motley Fool
Tempus AI price target raised by $15 at Guggenheim, here's why
Sep 26, 2025 • thefly.com
Why Tempus AI Stock Is Plunging This Week
Sep 25, 2025 • The Motley Fool
Why Tempus AI Stock Is Plunging This Week
Sep 25, 2025 • Nasdaq
Tempus AI Surges Since IPO as FDA Clearance Boosts Growth Outlook
Sep 21, 2025 • Yahoo Finance
Kuehn Law Encourages Investors of Tempus AI, Inc. to Contact Law Firm
Sep 19, 2025 • Morningstar.com
Kuehn Law Encourages Investors of Tempus AI, Inc. to Contact Law Firm
Sep 19, 2025 • PR Newswire
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises
Sep 18, 2025 • PR Newswire UK
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises
Sep 18, 2025 • PR Newswire
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises
Sep 18, 2025 • MarketScreener
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises
Sep 18, 2025 • Canada NewsWire
Cathie Wood's Ark Bets Big On Solana Treasury Play: Makes $162M Investment In Brera Holdings As Stock Explodes 225%
Sep 18, 2025 • Benzinga.com
Cathie Wood's Reshuffle Tuesday: Loads Up On AMD, Figma And Bullish, Trims Tempus AI
Sep 16, 2025 • Benzinga.com
What's Going On With Tempus AI Stock Monday?
Sep 15, 2025 • Benzinga.com
Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease
Sep 15, 2025 • PR Newswire
Why Tempus AI Is A High Stakes High Rewards Play?
Sep 12, 2025 • Trefis
Tempus AI: TEM Stock To $400?
Sep 12, 2025 • Forbes
Northwestern Medicine to adopt “David,” a generative AI copilot by Tempus AI Inc.
Sep 12, 2025 • The Cancer Letter
Tempus AI secures 510(k) for Pixel
Sep 12, 2025 • AuntMinnie
Tempus AI Receives FDA Clearance For Updated Tempus Pixel
Sep 11, 2025 • Nasdaq
Tempus AI: Rapid Growth or Future Decline?
Sep 11, 2025 • StocksToTrade
Northwestern Medicine Integrates Tempus AI’s “David” Clinical Assistant into EHR Platform
Sep 11, 2025 • Yahoo Finance
Why Tempus AI Stock Soared Nearly 14% Higher Today
Sep 11, 2025 • The Motley Fool
Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device
Sep 11, 2025 • MarketScreener
Biovica Q1 Interim Report May 2025 - July 2025
Sep 11, 2025 • Morningstar.com
Tempus AI Gains FDA Clearance For Updated Pixel To Boost Accuracy And Efficiency In Cardiac Imaging
Sep 11, 2025 • Benzinga.com
Inside the Clinical Decision Support Market: The Race to Make AI Work at the Point of Care
Sep 11, 2025 • MedCity News
Tempus AI Gets FDA's Clearance for Updated Tempus Pixel Cardiac Imaging Platform
Sep 11, 2025 • MarketScreener
Maze Therapeutics, Opendoor Technologies, Oxford Industries, VNET Group And Other Big Stocks Moving Higher On Thursday
Sep 11, 2025 • Benzinga.com
Biovica Q1 Interim Report May 2025 - July 2025
Sep 11, 2025 • PharmiWeb
Tempus AI, Inc. Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device
Sep 11, 2025 • MarketScreener
Tempus AI rises 14.4%
Sep 11, 2025 • thefly.com
Tempus AI: Strategic AI Advancements In Precision Oncology With Solid Stock Upside Potential
Sep 8, 2025 • Seeking Alpha
Tempus AI Joins Rank Of Stocks With RS Ratings Over 90
Sep 5, 2025 • Investor's Business Daily
Healthcare Dealmakers—UHG, Amedisys close merger; Walgreens acquired and more
Sep 5, 2025 • Fierce Healthcare
Northwestern Medicine Becomes First Health System to Integrate Tempus’ Generative AI Co-Pilot, David, Into Its EHR Platform
Sep 4, 2025 • Business Wire
Tempus AI: Expansive Opportunity As Healthcare Becomes More Heavily Scrutinized (TEM)
Sep 4, 2025 • Seeking Alpha
Tempus AI (TEM) Partners With Northwestern Medicine To Enhance AI-Powered Clinical Care
Sep 4, 2025 • Yahoo Finance
What's Fueling Tempus AI's Q2 Net Loss Improvement Momentum?
Sep 4, 2025 • Zacks Investment Research
Chicago tech entrepreneur Eric Lefkofsky has launched six unicorns, building a legacy far beyond Groupon
Sep 3, 2025 • Chicago Tribune
Tempus to Participate in Morgan Stanley’s 23rd Annual Global Healthcare Conference
Sep 3, 2025 • Business Wire
Tempus AI stock initiated with Buy rating at H.C. Wainwright on precision medicine growth
Sep 2, 2025 • Investing.com
Tempus AI initiated with bullish view at H.C. Wainwright, here's why
Sep 2, 2025 • thefly.com
This Penumbra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Sep 2, 2025 • Benzinga.com
3 Heavily Shorted Stocks That Could Prove the Bears Wrong
Sep 2, 2025 • MarketBeat
Amazon and Piper Sandler signed NYC’s largest office leases last month, both in Midtown West
Sep 2, 2025 • The Real Deal
Tempus AI, Inc. (TEM) Expands into Digital Pathology with Paige Acquisition
Aug 29, 2025 • Yahoo Finance
Tempus AI Insider Sold Shares Worth $24,637,581, According to a Recent SEC Filing
Aug 29, 2025 • MarketScreener
U.S. Concierge Medicine Market Size to Exceed USD 11.97 Billion by 2034 Driven by Rising Demand for Personalized and Preventive Healthcare
Aug 28, 2025 • Precedence Research
Tempus AI Adds Digital Pathology to Cancer Portfolio With Paige Acquisition
Aug 27, 2025 • GenomeWeb
Should Investors Rethink Tempus AI After Shares Double and New Novartis Collaboration?
Aug 26, 2025 • Yahoo Finance
Tempus inks $81M Paige buyout to support AI model development
Aug 26, 2025 • MedTech Dive
Tempus' Key Acquisitions Strengthen Its AI Healthcare Leadership
Aug 26, 2025 • Nasdaq
Tempus AI CEO open to more deals
Aug 26, 2025 • Axios
Tempus to acquire AI digital pathology company Paige
Aug 25, 2025 • Medical Device Network
Tempus AI acquires Paige for $81M
Aug 25, 2025 • Mobi Health News
Tempus AI or Butterfly: Which AI Health Tech Stock is a Buy Now?
Aug 25, 2025 • Yahoo Finance
Tempus Buying Paige In $81.25 Million Deal
Aug 25, 2025 • Pulse 2.0
Latham & Watkins Advises Tempus AI in Acquisition of Paige
Aug 23, 2025 • Latham & Watkins
The Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to Explode
Aug 23, 2025 • The Motley Fool
Can AI make clinical trials better?
Aug 23, 2025 • Investing.com
Tempus claims AI pathology developer Paige in $81M deal
Aug 22, 2025 • Fierce Biotech
Stocks To Watch: Tempus AI Sees RS Rating Rise To 88
Aug 22, 2025 • Investor's Business Daily
Tempus Announces the Acquisition of Paige
Aug 22, 2025 • Business Wire
Tempus AI Buys Paige
Aug 22, 2025 • MarketScreener
Tempus Announces the Acquisition of Paige
Aug 22, 2025 • MarketScreener
Strategic Partnerships Power Tempus AI's Healthcare Expansion
Aug 19, 2025 • Yahoo Finance
19 Silicon Valley AI Companies Pushing the Industry Forward
Aug 19, 2025 • Built In

Links

www.tempus.comLinkedInX (Twitter)Crunchbase

This role is listed on SalaryGuide for informational purposes. SalaryGuide is not the employer, recruitment agency, or hiring representative for this position. Hiring decisions and the application process are managed by the employer. SalaryGuide will never ask candidates to pay to apply for a job or request bank details or identification documents as part of an application.